NCR2 and neoplasm: Although several tumor cells and bacteria can bind NKp44–Ig fusion protein (87, 88), and NKp44 blocking via specific antibodies can decrease activated-NK cell-mediated cytolysis (84), as well as ILC3 cytokine production (22), the identity of NKp44 ligands triggering NK cells and ILC3 remains elusive.